文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

CAR T细胞治疗后治疗相关髓系肿瘤的临床特征与结局

Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.
PubMed 文献 · Blood Adv · 2026-10-07

多中心回顾性队列纳入399例成人治疗相关髓系肿瘤(t-MN),其中CAR T后56例、自体移植后98例、标准化疗/放疗后245例,并构建潜伏期匹配队列220例。CAR T后t-MN潜伏期短且总生存期独立不良,TP53克隆负荷不能完全解释,异基因移植仍为唯一潜在治愈手段。

要点

  • CAR T后t-MN中位潜伏期15.2个月,短于自体移植后38.0个月和标准治疗30.0个月。
  • 匹配队列中CAR T后t-MN中位OS 9.1个月,差于自体移植16.9个月和标准治疗18.7个月。
  • CAR T后t-MN全因死亡HR 1.98,调整TP53状态后仍为1.85,独立于TP53克隆负荷。

核心结论

  • CAR T细胞治疗后发生的t-MN具有独立生存劣势,且不能由TP53克隆负荷解释。
  • 异基因造血干细胞移植仍是此类患者唯一潜在治愈选择。

研究设计与样本

  • 多中心回顾性队列纳入399例成人t-MN,按既往治疗分为CAR T后56例、自体造血干细胞移植后98例、标准化疗/放疗后245例。
  • 构建最近邻潜伏期匹配队列220例。

主要发现

  • 中位潜伏期:CAR T后15.2个月,自体移植后38.0个月,标准治疗30.0个月,p<0.001。
  • 匹配队列中位OS:CAR T后9.1个月,自体移植后16.9个月,标准治疗18.7个月,p=0.013。
  • 多变量Cox模型全因死亡HR:CAR T后1.98(95%CI 1.33-2.94),自体移植后0.99(95%CI 0.74-1.32),均以标准治疗为参照。
  • 调整TP53状态后CAR T后HR 1.85(95%CI 1.21-2.82);分子数据近完整的时代限制队列中HR 2.15(95%CI 1.23-3.76)。
  • TP53变异等位基因频率独立预测OS,每增加10%的HR为1.14(95%CI 1.03-1.26)。

临床怎么用

  • CAR T后出现血细胞减少或形态学异常时应警惕t-MN,其潜伏期可短至15.2个月。
  • 对CAR T后t-MN应评估TP53状态,但TP53克隆负荷不能完全解释生存劣势。
  • 异基因造血干细胞移植应作为潜在治愈手段尽早评估。

局限性

  • 回顾性多中心队列设计可能存在选择偏倚和残余混杂。
  • 异基因移植的HR置信区间包含1,获益证据尚不确切。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related myeloid neoplasms (t-MN) after chimeric antigen receptor (CAR) T-cell therapy occur with short latency, but whether they carry an independent survival disadvantage is unclear. We assembled a multicenter retrospective cohort of 399 adults with t-MN after CAR T-cell therapy (n=56), autologous hematopoietic cell transplantation (auto-HCT; n=98), or standard chemotherapy/radiation (n=245), and constructed a nearest-neighbor latency-matched cohort (n=220). Median latency was 15.2 months for post-CAR-T versus 38.0 and 30.0 months for post-auto-HCT and standard therapy (p<0.001). In the matched cohort, median overall survival (OS) was 9.1 months for post-CAR-T versus 16.9 and 18.7 months for post-auto-HCT and standard therapy (p=0.013). In multivariable Cox models, the hazard ratio for overall mortality was 1.98 (95% CI 1.33-2.94) for post-CAR-T and 0.99 (95% CI 0.74-1.32) for post-auto-HCT, each relative to standard therapy; The post-CAR-T estimate was 1.85 (95% CI 1.21-2.82) after adjustment for TP53 status and 2.15 (95% CI 1.23-3.76) in an era-restricted cohort with near-complete molecular data. TP53 variant allele frequency independently predicted OS (HR 1.14 per 10% increment, 95% CI 1.03-1.26). The hazard ratio for allogeneic HCT, modeled as a time-varying covariate, was 0.74 (95% CI 0.52-1.06). Post-CAR-T t-MN carries an independent survival disadvantage not explained by TP53 clone burden; allogeneic HCT remains the only potentially curative option.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jain MD, Ali A, Roman Diaz J, et al. Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy. Blood Adv. 2026. PMID: 42842872. doi:10.1182/bloodadvances.2026021831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。